The biggest peptide story of 2026 may not be a new study. It may be the FDA review calendar. BPC 157, TB 500, MOTS c, Semax, and other peptides are headed into FDA advisory review The trend of unproven peptides is spreading through influencers and RFK Jr. allies CNN The U.S. Food and Drug Administration is moving toward allowing compounding pharmacies to produce more than a dozen injectable peptides that were banned because of potentially significant safety risks, the New York FDA Compliance for Peptide Therapy and BPC 157 Holt Law